Anokion

Executive Summary

Anokion is a Swiss biotechnology company founded in 2015, based in Lausanne, dedicated to developing antigen-specific immunotherapies for autoimmune diseases. Unlike traditional immunosuppressive approaches, Anokion's platform aims to restore the body's natural immune tolerance by targeting the root cause of autoimmunity. The company's technology leverages proprietary antigen-specific strategies to selectively modulate immune responses, potentially offering safer and more durable treatments for conditions such as celiac disease, multiple sclerosis, and type 1 diabetes. As a private company with no disclosed funding rounds or valuation, Anokion likely operates in preclinical or early clinical stages, focusing on advancing its lead candidates through proof-of-concept studies. The biotech's innovative approach addresses a significant unmet need in autoimmune therapeutics, where current treatments often involve broad immunosuppression with side effects. With its Swiss base and specialized focus, Anokion is positioned to attract partnerships or financing as it progresses toward clinical validation.

Upcoming Catalysts (preview)

• H2 2026Phase 1 Clinical Trial Initiation for Lead Candidate70% success
• Q3 2026Preclinical Data Presentation at Major Conference90% success
• H1 2026Partnership or Licensing Deal for Key Program30% success